CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

The critical role of gut microbiota in obesity

Open access
Cheng, Zilu, Zhang, Li, Yang, Ling, Chu, Huikuan · 2022 · Frontiers in Endocrinology

Abstract

Obesity is a global epidemic characterized by energy disequilibrium, metabolic disorder, fat mass development, and chronic low-grade inflammation, which significantly affects the health state of individuals of all ages and strains the socioeconomic system. The prevalence of obesity is rising at alarming rates and its etiology involves complicated interplay of diet, genetic, and environmental factors. The gut microbiota, as an important constituent of environmental factors, has been confirmed to correlate with the onset and progression of obesity. However, the specific relationship between obesity and the gut microbiota, and its associated mechanisms, have not been fully elucidated. In this review, we have summarized that the microbial diversity was significantly decreased and the Firmicutes/Bacteroidetes ratio was significantly increased in obesity. The altered gut microbiota and associated metabolites contributed to the progression of the disease by disrupting energy homeostasis, promoting lipid synthesis and storage, modulating central appetite and feeding behavior, as well as triggering chronic inflammation, and that the intentional manipulation of gut microbiota held promise as novel therapies for obesity, including probiotics, prebiotics, and fecal microbiota transplantation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fendo.2022.1025706

Cites

Statistics

Figures

Figure 1 Energy homeostasis disruption. Abundant nutrient transporters (CD36, Glut2) and various primary fermentation enzymes (α-amylases and amylomaltases) caused by altered gut microbiota in obesity improve the efficiency of digestible energy uptake and promote monosaccharides and SCFAs production. Moreover, the production of SCFAs was also enhanced by the interspecies H2 transfer between bacteria and archaea. The produced monosaccharides and SCFAs in the gut tract can be absorbed by the host. The decrease of Bacteroides and Lactobacillus in obesity leads to the reduction of bile acids, which inactivates TGR5/FXR-mediated signaling pathway in brown adipose tissue, thus reducing uncouple mitochondrial function, thermogenesis, and white adipose tissue browning. Additionally, the presence of SCFAs suppresses FIAF secretion in the intestine, which then inhibits catabolic process, such as β-oxidation. Taken together, the altered gut microbiota in obesity results in more energy uptake and less energy expenditure, which contributes to the progression of obesity. SCFAs, short-chain fatty acids; TGR5, Takeda G protein-coupled receptor 5; FXR, Farnesoid X Receptor; FIAF, fasting-induced adipose factor.
Figure 1 Energy homeostasis disruption. Abundant nutrient transporters (CD36, Glut2) and various primary fermentation enzymes (α-amylases and amylomaltases) caused by altered gut microbiota in obesity improve the efficiency of digestible energy uptake and promote monosaccharides and SCFAs production. Moreover, the production of SCFAs was also enhanced by the interspecies H2 transfer between bacteria and archaea. The produced monosaccharides and SCFAs in the gut tract can be absorbed by the host. The decrease of Bacteroides and Lactobacillus in obesity leads to the reduction of bile acids, which inactivates TGR5/FXR-mediated signaling pathway in brown adipose tissue, thus reducing uncouple mitochondrial function, thermogenesis, and white adipose tissue browning. Additionally, the presence of SCFAs suppresses FIAF secretion in the intestine, which then inhibits catabolic process, such as β-oxidation. Taken together, the altered gut microbiota in obesity results in more energy uptake and less energy expenditure, which contributes to the progression of obesity. SCFAs, short-chain fatty acids; TGR5, Takeda G protein-coupled receptor 5; FXR, Farnesoid X Receptor; FIAF, fasting-induced adipose factor.CC BY · PubMed Central
Figure 2 Lipid synthesis and storage. The reduction of bile acids in obesity inhibits FXR in hepatocytes, which ultimately induces the transactivation of SREBP1c mediated by SHP, thus contributing to hepatic de novo lipogenesis. Decreased bile acids are also unfavorable for FGF15/FGF19 secretion in the intestine, which then inactivates FGFR4 on hepatocytes and promotes SREBP1c transactivation indirectly by inhibiting SHP, and directly by inducing PGC1β and repressing STAT3, ultimately enhancing hepatic lipogenesis. Moreover, the SREBP1 and ChREBP expression can also be promoted by elevated glucose level which correlates with higher Glut2 expression induced by altered gut microbiota in obesity. In addition, the increased SCFAs in obesity, especially acetates and butyrates, can act as precursors for FA or cholesterol synthesis. The reduced L. paracasei in obese individuals putatively contributes to lipid storage by releasing the inhibition of LPL induced by ANGPTL4. Furthermore, elevated levels of proinflammatory cytokines and metabolic endotoxemia induced by LPS correlate with insulin resistance and the proliferation of adipocytes and adipocyte precursor cells, which all make contributions to lipid storage. FXR, Farnesoid X Receptor; SREBP1c, sterol regulatory binding protein1c; SHP, small heterodimer partner; FGF, fibroblast growth factor; PGC1β, peroxisome proliferator-activated receptor-γ coactivator 1β; STAT3, signal transducer and activator of transcription; ChREBP, carbohydrate response element binding protein; SCFAs, short-chain fatty acids; FA, fatty acids; LPL, lipoprotein lipase; LPS, lipopolysaccharide.
Figure 2 Lipid synthesis and storage. The reduction of bile acids in obesity inhibits FXR in hepatocytes, which ultimately induces the transactivation of SREBP1c mediated by SHP, thus contributing to hepatic de novo lipogenesis. Decreased bile acids are also unfavorable for FGF15/FGF19 secretion in the intestine, which then inactivates FGFR4 on hepatocytes and promotes SREBP1c transactivation indirectly by inhibiting SHP, and directly by inducing PGC1β and repressing STAT3, ultimately enhancing hepatic lipogenesis. Moreover, the SREBP1 and ChREBP expression can also be promoted by elevated glucose level which correlates with higher Glut2 expression induced by altered gut microbiota in obesity. In addition, the increased SCFAs in obesity, especially acetates and butyrates, can act as precursors for FA or cholesterol synthesis. The reduced L. paracasei in obese individuals putatively contributes to lipid storage by releasing the inhibition of LPL induced by ANGPTL4. Furthermore, elevated levels of proinflammatory cytokines and metabolic endotoxemia induced by LPS correlate with insulin resistance and the proliferation of adipocytes and adipocyte precursor cells, which all make contributions to lipid storage. FXR, Farnesoid X Receptor; SREBP1c, sterol regulatory binding protein1c; SHP, small heterodimer partner; FGF, fibroblast growth factor; PGC1β, peroxisome proliferator-activated receptor-γ coactivator 1β; STAT3, signal transducer and activator of transcription; ChREBP, carbohydrate response element binding protein; SCFAs, short-chain fatty acids; FA, fatty acids; LPL, lipoprotein lipase; LPS, lipopolysaccharide.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 126 · Cited by 233

Metadata

Authors
Cheng, Z., Zhang, L., Yang, L., & Chu, H.
Affiliations
Wuhan Union Hospital (CN)
Corresponding author
  • Yang, Ling
  • Chu, Huikuan
Venue
Frontiers in Endocrinology
Published
2022-10-20
Volume
13
Pages
1025706-1025706
ISSN
1664-2392 (ISSN-L)
OpenAlex
W4306930880
Cited by
233
References
126
Citations by year
2026: 43 · 2025: 81 · 2024: 76 · 2023: 28 · 2022: 4
FWCI
4.97
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Endocrinology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (No.82000561 to HC; No.81974078,81570530, 81370550 to LY, No.82270614 to LY)
  • Natural Science Foundation of Hubei Province (No.2019ACA1333 to LY)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
Keywords
gut microbiota, obesity, Firmicutes/Bacteroidetes ratio, microbial diversity, energy homeostasis, lipid metabolism, appetite regulation, feeding behavior, low-grade inflammation, obesity etiology, probiotics, prebiotics, fecal microbiota transplantation, obesity treatment
MeSH terms
Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Humans, Inflammation, Obesity, Prebiotics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The critical role of gut microbiota in obesity. https://app.cochat.ai/papers/10.3389/fendo.2022.1025706
The paper
Cheng, Z., Zhang, L., Yang, L., & Chu, H. (2022). The critical role of gut microbiota in obesity. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1025706

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.